SUBSCRIBE
SUBSCRIBE

BioSpace Insights

The BioSpace Insights team performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.

Hourglass lying on pink background - Concept of time and woman
Insights
Validated Mechanisms, Strong Data Beat Hype in Longevity Investing
Longevity is a long-standing buzzword in life sciences, but it now has staying power. The smart trajectory is to stop chasing aging as an abstract target and concentrate on specific mechanisms that can clearly advance specific, age-related diseases, according to two investors in a discussion with BioSpace.
March 23, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Insights
Inside the Race to Build the Next Generation of AI Drug Discovery Platforms
In this episode of Denatured, you’ll listen to Viswa Colluru, CEO and founder of Enveda and Akshay Rai, principal, Healthcare & Biotech Investments at Premji Invest. We speak about how AI platforms must now prove themselves through proprietary data, focused pipelines and clinical readouts in competitive diseases to garner investor interest.
March 19, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Job Trends
Report: 2026 U.S. Life Sciences Salary Report
BioSpace‘s 2026 U.S. Life Sciences Salary Report delivers a comprehensive look at how salaries, bonuses and benefits evolved over the past year amid ongoing economic pressure and workforce recalibration. It uncovers not just what people are earning, but how they’re thinking about compensation, career moves and total rewards in 2026.
March 19, 2026
 · 
1 min read
 · 
BioSpace Insights
IN PARTNERSHIP WITH PATSNAP
Webinar: The Agentic Test: Can AI Actually Accelerate Drug Development and Break Down Silos Across Pharma?
Every biopharma R&D and investment decision could be guided by connected intelligence. Join us to hear firsthand how agentic workflows and enterprise-scale data are helping drug developers move faster from molecule to market with greater confidence.
March 18, 2026
 · 
1 min read
 · 
BioSpace Insights
IN PARTNERSHIP WITH DIA
Webinar: Operationalizing AI in Drug Development: Inside DIA’s Global AI Consortium
This webinar introduces the DIA Artificial Intelligence Consortium, a neutral, public‑private partnership that convenes regulators, biopharmaceutical companies, academia, and technology providers, including FDA, Health Canada, MHRA, PMDA, IQVIA, Gilead, Otsuka, BeOne Medicines, Beth Israel Deaconess Medical Center–Yale School of Medicine, and others.
March 17, 2026
 · 
1 min read
 · 
BioSpace Insights
Symbolic image: Life as a hurdling - person faces challenges
Insights
AI Drug Discovery Platforms Face New Investor Bar
In a highly competitive space, AI platforms must now prove themselves through proprietary data, focused pipelines and clinical readouts in competitive diseases. Promises of faster, cheaper drug discovery are not enough to entice strong investor engagement.
March 17, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Insights
From Two Trials to One, Sponsors Face a Higher Standard
In this episode of Denatured, you’ll listen to Oxana Iliach, senior director of regulatory strategy at Certara and Vera Pomerantseva, director of product management for risk-based quality management at eClinical Solutions. We speak about how the FDA’s latest decision to have one, rather than two pivotal studies, for new drug applications raises the bar for data collection and risk-based management.
March 12, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Flat 3d isometric business people came from different way but have same target. Business team and target concept.
Insights
Single Pivotal Trials Demand Stronger Data and Risk Strategies
Single-trial approvals are raising the bar on trial design and execution. The new paradigm is pushing sponsors to plan earlier, step up their data and risk‑based quality management and use modeling and AI to generate one compelling, regulator‑ready evidence package.
March 10, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Insights
From Grants to Family Offices: Building a Unified Financing Strategy in Biotech
In this episode of Denatured, you’ll listen to Ram May-Ron, managing partner at FreeMind Group, and Ravi Kiron, managing director at Biopharma Strategy Advisors. We’ll be speaking about how to combine nondilutive funding and family office money into a unified strategy that gets companies through the drug development valley of death.
March 5, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
cloud with rain of coins on blue background. minimal concept of investment, success and cryptocurrencies. 3d rendering
Insights
Rethinking Biotech’s Valley of Death as Federal Grants and Family Offices Step In
With fresh billions unlocked in the 2026 U.S. budget and mission‑driven family offices recalibrating after a “nuclear winter,” early stage biotechs are rewriting their financing strategies around nondilutive capital and targeted private wealth.
March 4, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
IN PARTNERSHIP WITH MEDSIR
Webinar: The Future is Collaborative: Transforming Clinical Trials
This webinar explores how collaborative-initiated trials and Investigator-Initiated Trials (IITs) are complementing traditional drug development to accelerate innovation, advance precision medicine, and address clinically meaningful questions.
March 3, 2026
 · 
1 min read
 · 
BioSpace Insights
Insights
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
In this episode of Denatured, you’ll be listening to Indu Navar, CEO and founder of EverythingALS and Dr. Olga Uspenskaya, chief medical officer at VectorY Therapeutics. We’ll be speaking about patient-pharma collaborations accelerating trials and hope, advances in ALS biology understanding and biomarker-driven endpoints.
February 26, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
IN PARTNERSHIP WITH API
Webinar: Lean Derisking: Taking Your Proof of Concept to the Clinic
Taking an early proof of concept into preclinical and clinical development is a costly and complex process. But there are strategic ways to streamline the process and reduce risk and costs. In this webinar, you’ll hear directly from Nobel Laureate Sir Michael Houghton and experts from Applied Pharma, who bring decades of real-world success and deep scientific expertise.
February 24, 2026
 · 
1 min read
 · 
BioSpace Insights
Insights
Historic ALS Investment Signals New Treatment Momentum
The U.S. Congress greenlit a historic $315 million in federal ALS research funding for 2026 amid Rare Disease Month, spotlighting biotech progress like VectorY Therapeutics’ first patient dosing in its TDP-43-targeting PIONEER-ALS trial and EverythingALS’ pharma consortia driving biomarker innovations and trial alignment.
February 23, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Insights
Redefining Obesity Treatment Beyond GLP-1 Limits
In this episode of Denatured, you’ll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. We’ll discuss next-generation obesity solutions tackling GLP-1’s muscle loss and adherence challenges, through innovative muscle preservation, oral administration and combination therapy.
February 19, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Load More